Isis Pharmaceuticals Reports Fifth Positive Phase 2 Data Set for ISIS-APOCIII Rx Showing Significant Reductions in Triglyceride and ApoC-III Levels
Fifth ? Where have you been ? isis has presented "potent, powerful " data for 24 years on phase 2s. NO GOOD DRUGS ! Go pump this junk on the iv board ! You make no sense !
Go away! Idiot. Nobody wants you here!
Smart information . Genius is a real headcase.
Why no disclosure of non-HDL changes like in the prior reports? Would have also liked to have seen a quantification of the ISRs.
On slides, ISRs reported in less than 10% of injections. That's excellent. In comparison, ISRs reported in 90% of patients treated with mipomersen in its phase III (and placebo in that study reported 32% ISRs)